RGCC

# Personalized cancer testing for precise care

rgccsea.com

contents

# Table of contents

# About us

Research Genetics Cancer Center (RGCC) was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine using the information in a patient's genes.

Using world-leading technology, equipment and innovative techniques, our team of scientists have developed a range of cancer tests that give healthcare professionals comprehensive information about a patient's genetics, physiology and immune profiles. This diversion from a 'one-size-fits all approach' uses data to determine what treatment will work best.

Most importantly, by looking at a person's genetics, physiology and immune profiles, our cost-effective and highly accurate tests will give you the information you need to formulate effective personalized treatment plans.

**20**
**Years**

**80,000**
**Patients**

**96,700**
**Tests done**

# Laboratory facilities

As a global organization, we work in collaboration with branch offices and distributors to provide a worldwide service. Our head office is in Switzerland, and we have state-of-the-art laboratory facilities based around the world.

Our laboratories in Europe and India are equipped with world-leading technology and staffed by experts in their fields. Using innovative techniques, they provide trusted and timely information so doctors and patients can take action based on their results.

Baar,
**Switzerland**

Halle,
**Germany**

Florina,
**Greece**

Hyderabad,
**India**

# Our renowned accreditation

Our lab is **ISO 15189 and CAP-accredited,** ensuring rigorous validation, precision, and reproducibility in all testing methodologies, including CTC detection.

ISO 15189 accreditation confirms compliance with globally recognized medical laboratory standards, while CAP accreditation further strengthens our commitment to diagnostic accuracy through continuous quality assessment. These accreditations directly support the reliability of Oncotrace's sensitivity and specificity.

These certifications ensure that RGCC's laboratory meets **the highest standards for accuracy, precision, and reliability** in clinical testing.

1. **ISO 15189 (Medical Laboratories – Quality & Competence)**
   - Recognized **internationally for clinical lab quality and diagnostic accuracy.**
   - Ensures **rigorous validation, reproducibility, and performance testing** of laboratory methods, including CTC detection.
   - Demonstrates **compliance with international standards for sensitivity & specificity testing.**

2. **CAP Accreditation (College of American Pathologists)**
   - CAP **sets laboratory standards beyond CLIA and FDA requirements,** ensuring high precision in testing methodologies.
   - Focuses on **maintaining the accuracy of test results and ensuring reproducibility,** which directly supports the **validity of Oncotrace's sensitivity & specificity.**
   - CAP-accredited labs undergo r**egular inspections and proficiency testing** to verify diagnostic accuracy.

3. **CLIA Certification (Clinical Laboratory Improvement Amendments)**
   - Required for **laboratories performing human diagnostic testing in the U.S.**
   - Ensures test methods, including CTC detection, meet **federal standards for analytical validity.**
   - Strengthens the reliability of test results through **compliance with stringent lab performance criteria.**

# RGCC Tests

## Onco-D-clare

Onco-D–clare, an advanced cancer screening test designed to detect cancerous cells before symptoms manifest. Utilizing state-of-the-art technology that merges molecular biology with artificial neural networks, this liquid biopsy screening test provides individuals with vital insights into their cancer risk. The test represents a proactive step towards early cancer detection and informed well-being. This test offers a proactive approach to managing cancer risk.

## Oncotrace

Oncotrace is an important step in the management and follow-up of a cancer treatment regimen. It gives us information on the current CTC count as well as the profile of how aggressive these cells are through the study of the Cancer Stem Cell (CSC) markers. By studying cancer behavior at a molecular level, doctors and patients can monitor the activity of tumor markers responsible for migration, proliferation, resistance, and metastasis.

## Onconomics Plus

Onconomics Plus is a one-stop solution for choosing personalized treatment plans. Onconomics Plus can show you how effective specific anti-cancer drugs, targeted therapies and natural treatments are on individual cancer cells. It provides a comprehensive breakdown of the most suitable and successful treatments for cancer.

## Oncotrail

Oncotrail is designed for specific cancers, i.e. Breast, Colon, GI, Melanoma, Prostate, and Sarcoma. The purpose of the test is to benchmark the aggressiveness of these tumors as well as to track the current management of these cancers. We use this test to monitor these cancers during cancer treatment and when a patient is in remission. It will check for CTCs as well as provide genetic insights into the nature of the CTCs.

## Oncocount

Oncocount is a useful tool for physicians and patients alike. By detecting the presence of circulating tumour cells (CTCs) and quantifying their concentration in the bloodstream, this diagnostic tool offers vital information about the presence of CTCs. The higher the number of CTCs, the higher the spread of the disease.

## aCGH

Using a technique called array comparative genomic hybridisation (aCGH) , our scientists are able to detect the chromosomal abnormalities within genes. This test assists in determining the potential location of the Primary Tumour.

RGCC tests use cutting-edge technologies
and are validated by years of research.

The following section details the technologies used in our tests:

# Circulating Tumor Cell (CTC) technology

## What are CTCs?

CTCs are cancer cells that break away from the primary tumor and enter the bloodstream, facilitating metastasis. The CTCs will transit and become invasive in secondary tissues or organs.

## Our technology to select CTCs

### Flow Cytometry - Negative Selection & Positive Selection




Sensitivity: 86.2%
Specificity: 83.9%

1. CTC enrichment by density gradient centrifugation:
Both negative and positive selection methods are employed to ensure the acquisition of the most comprehensive information.

2. Negative selection is performed by using what is called a “metastatic gate” to gate out unwanted cell.

3. Positive selection is performed by studying the markers on identifying the CTCs.

While most CTC tests separate out CTCs by detecting the presence of receptors (for example EPCAM), and this is called positive selection, we at RGCC employ negative selection first. We will use "metastatic gate" to gate out unwanted cell. As we know that while EPCAM is a common protein on CTCs, there are some populations of CTCs that do not express EPCAM receptors but other types of proteins instead. We apply negative selection so as not to miss these heterogenous populations of cancer cells.

### Select the wanted cells based on real-time sampling, not spike samples

Spiked samples are samples prepared by adding a sizeable amount of known matrix that we are targeting (like a specific cell line) and then assessing the number of positive samples that the tests are able to detect. This is usually done to portray a very high, close to 100% **sensitivity rate**. This does not truly reflect the sensitivity of detection in a real sample, or in real life samples. At RGCC, we gauge our sensitivity based on real life samples, with real results.




## Why is monitoring CTCs important?

Detecting and quantifying CTCs can provide a snapshot of tumor activity and metastatic potential.

CTCs are vital for assessing disease progression, treatment effectiveness, and potential relapse.



Tumor activity



Metastatic potential

Disease progression

Treatment effectiveness



Potential relapse

## RGCC tests that apply this technology

**The results from RGCC tests using CTC technology are not for diagnostic or health screening purposes.**

| RGCC test | Usages | Target Patients |
|---|---|---|
| Oncotrace | Oncotrace is one of the best tools for monitoring treatment response and patient condition, providing valuable insights for personalized precision medicine when used correctly | ✓ Patients who are positive from Onco-D-clare<br>✓ Patients who want to have a clear picture of their cancer status and treatment options<br>✓ For monitoring progress of cancer treatment |
| Onconomics Plus | Providing information of CTC count, oncogen, and analyzing the sensitivity and resistance factors of over 50 chemotherapeutic drugs, 60+ targeted drugs, and 50+ natural substances on cancer cells to see which are effective for the patients | ✓ Patients who are seeking the best treatment options for their cancer |

| RGCC test | Usages | Target Patients |
|---|---|---|
| Oncocount | A powerful tool for detecting the presence of CTCs and quantifying their concentration in the bloodstream | ✓ For monitoring progress of cancer treatment |
| Oncotrail | Specifically designed for patients with confirmed diagnoses of certain cancers (i.e. Breast, Colon, GI, Melanoma, Prostate, and Sarcoma), this test tracks circulating tumor cells (CTCs) to assess their presence and concentration and also markers in cancer to assess origin and activity of cancer cells | ✓ For monitoring progress of cancer treatment for specific cancers (i.e. Breast, Colon, GI, Melanoma, Prostate, and Sarcoma) |

# Examples of markers in the report

| Markers | Indication |
|---|---|
| Nanog<br>OKT-4<br>Sox-2 | ✓ Nanog is a receptor on a cancer stem cell ( like a button )<br>✓ OKT-4 and SOX-2: it combines to create a dimer that triggers off Nanog. (pressing the button)<br>✓ After Nanog is triggered, the cancer stem cell will split into 2 cells: 1 normal cell, and a malignant clone. (this new clone may be chemo resistant to current therapies) |
| c-MET | High c-MET expression in testing indicates CTCs are actively trying to metastasize, suggesting a more aggressive cancer phenotype. |
| CD15, CD30, CD34, CD19 | Markers for various hematologic malignancies, essential for diagnosing and classifying leukemia and lymphoma. |
| BCR-ABL | A fused protein expressed in hematological malignancies and in GIST. The existence of this chimeric protein reveals an aggressive phenotype. This protein can be a target for drugs like imatinib mesylate (Gleevec). This fusion protein is considered a primary oncogenic driver of chronic myelogenous leukemia (CML). If expressed, it is diagnostic for CML. Its function is as a fusion protein related to a resistant phenotype. |
| EpCAM | ✓ Plays a role in tumorigenesis and metastasis of carcinomas.<br>✓ Acts as a potential prognostic marker.<br>✓ Can be targeted in immunotherapeutic strategies. |
| panCK | If panCK is positive – possible indication of breast, colon, pancrease or lung cancer. |
| MUC-1 | If Muc-1 is positive – most likely to be breast cancer. |

| Scenario | Indication |
|---|---|
| Decrease in CTCs, Unchanged Markers | Indicates reduction in less aggressive CTCs - Dominant, aggressive CTCs are still active; suggests partial treatment success. |
| Decrease in Both CTCs and Markers | Indicates significant therapeutic response and improved patient prognosis - Reflects a reduction in both non-dominant and dominant CTCs. |


Scan these **QR codes** and watch the videos to know more about these tests

Oncotrace

Onconomics Plus

# PBMC technology

## What is PBMC?

PBMCs are key players in your immune system, including T cells, B cells, NK cells, and Monocytes. These cells are responsible for identifying and responding to abnormal cells in your body, including cancer cells. By analyzing PBMCs, we can detect early signs of cancer before it even becomes visible in other tests.

## Why is PBMC used in our test?

By analyzing gene expression of PBMCs, we can detect the earliest signs of cancer before it even becomes visible in other tests. The expression profile derived from this analysis enables the test to classify the given blood sample as either a cancerous or healthy sample, with remarkable accuracy.

## Peripheral blood mononuclear cells




# RGCC test that apply this technology

| RGCC tests | Usages | Target Patients |
|---|---|---|
| Onco-D-clare | Early Cancer Detection, detecting cancer before the symptoms and tumors show up | ✓ People with a family history of cancer<br>✓ People who belong to a high-risk group for cancer<br>✓ Anyone who is seeking a highly sensitive and accurate early cancer screening test for proactive health management |

## What if Onco-D-Clare is positive?

Next step is to conduct conventional investigations like tumor markers, imaging tests, and etc. to confirm the presence of cancer. Simultaneously conduct Oncotrace testing, then:

| Scenario | Next Step |
|---|---|
| Both imaging and Oncotrace are negative | ✓ Consider repeating Onco-D-clare after 6 months.<br>✓ Lifestyle changes and complementary therapies might be recommended. |
| Oncotrace is positive | ✓ Treat the patient as if cancer is present, even at an early stage (Stage 0).<br>✓ Proceed with Onconomics Extract Plus/ Onconomics Plus testing.<br>✓ Consider an additional test for genetic characterization (e.g. aCGH) to further understand the cancer's nature.<br>✓ Implement full biological treatment protocols, excluding chemotherapy, surgery, or radiotherapy.<br>✓ Undergo diagnostic imaging to look for tumors.<br>✓ aCGH test to identify the primary source of the cancer. |

| Scenario | Next Step |
|---|---|
| Imaging is Positive | ✓ Implement full biological treatment protocols, including chemotherapy, surgery, or radiotherapy. |

Scan this **QR code** and watch the video to know more about this test

Onco-D-clare

# aCGH technology

## What is aCGH test?

The aCGH test is a microarray-based technique and the most precise tool available today detects the unbalanced structural and numerical chromosomal abnormalities that exist in a cancer patient. The test is beneficial when a patient may be diagnosed with a cancer of unknown origin.

## Why aCGH test?

- ✓ The test result provides experts with a clear understanding of the patient's genes and detects the primary origin of carcinoma.
- ✓ It helps patients to understand more about the risk of developing cancer through unique and personalized chromosomal analysis.
- ✓ It detects the potential location of the primary tumor.

## Work flow of aCGH test?

**Extract & Label DNA**
Extract genomic DNA from a test and a reference sample and label one with a red fluorescent dye and the other a green fluorescent dye



**Hybridize & Wash**
Mix and hybridize to a microarray printed with thousands of oligonucelotide probes then wash

**Scan**
Detect red and green signals using a fluorescence scanner

**Analyze Data**
Compute and report gains or losses in the test DNA using software

## aCGH test is beneficial to which group of people:

The test is beneficial when a patient may be diagnosed with a cancer of unknown origin.

# Your Journey of Personalized Cancer Testing for Precise Care

| RGCC tests | Usages | Target Patients |
|---|---|---|
| Onco-D-clare | Early cancer detection, detecting cancer before the symptoms and tumors show up | ✓ People with a family history of cancer<br>✓ People who belong to a high-risk group for cancer<br>✓ Anyone who is seeking a highly sensitive and accurate early cancer screening test for proactive health management |
| Oncotrace | Oncotrace is one of the best tools for monitoring treatment response and patient condition, providing valuable insights for personalized precision medicine when used correctly | ✓ Patients who are positive from Onco-D-clare<br>✓ Patients who want to have a clear picture of their cancer status and treatment options<br>✓ For monitoring progress of cancer treatment |

| RGCC tests | Usages | Target Patients |
|---|---|---|
| Onconomics Plus | Providing information of CTC count, oncogen, and analyzing over 50 chemotherapeutic drugs, 60+ targeted drugs, and 50+ natural substances on cancer cells to see which are effective for the patients | ✓ Patients who are facing different treatment options for their cancer |
| Oncocount | A powerful tool for detecting the presence of CTCs and quantifying their concentration in the bloodstream | ✓ For monitoring progress of cancer treatment |
| Oncotrail | Specifically designed for patients with confirmed diagnoses ofcertain cancers (i.e. Breast, Colon, GI, Melanoma, Prostate, and Sarcoma), this test tracks circulating tumor cells (CTCs) to assess their presence and concentration and markers in cancer to assess origin and activity of cancer cells | ✓ For monitoring progress of cancer treatment for specific cancers (i.e. Breast, Colon, GI, Melanoma, Prostate, and Sarcoma) |

| RGCC tests | Usages | Target Patients |
|---|---|---|
| aCGH | By identifying chromosomal abnormalities, aCGH test assists in determining the potential location of the primary tumor, providing critical information for diagnosis and treatment planning | ✓ Patient with an unknown origin of cancer cells |
| Immune-Frame | The Immune-Frame would provide insights into the current state of a person's immune system. Immune-Frame would evaluate the strengths and weaknesses of the immune system in totality. This is vital to cancer survival and the selection of various immunotherapeutic options that are precise | ✓ Immune-Frame is a prerequisite in cell therapies both pre-administration, in order to set up the baseline. But also in specific time intervals post-administration, in order to evaluate the efficiency of the therapy |

| | Onco-D-clare | Oncocount | Oncotrace / Oncotrail | Onconomics | aCGH | ChemoSNiP |
|---|---|---|---|---|---|---|
| **Purpose** | Screening | Baseline Monitoring | Baseline Monitoring | Personalised protocol | To detect potential location of a primary tumour | Personalised protocol |
| **Method** | Gene expression (qPCR) Machine learning algorithms | Fluorescence-activated cell sorting (FACS) | Fluorescence-activated cell sorting (FACS) Protein expression | Gene and protein expression Vialbility-chemosensitivity, flow cytometry | Fluorescence-activated cell sorting (FACS) Microarrays | Sequencing (TAQ-man Probes) |
| **Cell analysed** | PBMCs | CTCs | CTCs | CTCs | CTCs | Genomic DNA |
| **Phenotype markers** | Yes | Limited | Yes | | | |
| **Stemness markers** | | | Yes | | | |
| **Oncogenes** | Yes | | | Yes | | |
| **Resistance markers** | | | | Yes | | |
| **Chemotherapeutic agents** | | | | Yes | | |
| **Natural extracts** | | | | Yes | | |
| **Radiotherapy hyperthermia sensitivity** | | | | Yes | | |
| **Primary origin of cancer** | | | | | Yes | |

# Comparison of CTC and ctDNA for cancer testing

| | CTC | ctDNA |
|---|---|---|
| Real-time monitoring of tumors | Yes<br>reflects current tumor status and metastatic potential | Limited<br>based on circulating DNA fragments from dead or dying cancer cells |
| Tumor Heterogeneity | High<br>detection capability of different CTC subpopulations | Limited<br>provides pooled genetic data |
| Phenotype Expression | Yes | No |
| Directly testing cancer drugs on cancer cells | Yes<br>CTCs can be isolated from blood samples and cultured to evaluate their response to various cancer drugs and natural substances | No |

# Let us dive
## into the world of RGCC tests



# Changing the landscape of early detection of cancer

## Onco-D-clare test

# Onco-D-clare

Onco-D-clare is a cancer screening test designed to identify cancer even before the symptom's onset. With the ease of a simple blood draw, you can now detect cancer long before any symptoms emerge. Onco-D-clare opens an early door to personalized health insights.




## How does Onco-D-clare works?

- ✓ Onco-D-clare based on the synergy of molecular biology with machine learning algorithms.
- ✓ Peripheral blood mononuclear cells isolated from blood sample, and gene expression analysis is performed in more than 90 genes.
- ✓ Their expression profile is then used for classification of sample as cancer or healthy.

Onco-D-clare → looks for → Gene expression profile → Identify cancer even before the symptom's onset

## How does Onco-D-clare help?

- ✓ The Onco-D-clare test goes beyond traditional screening, aiming to detect cancer at its earliest stages.
- ✓ The Onco-D-clare test is designed as an early screening test for patients who do not have a cancer diagnosis but may want to stay informed about their risk.
- ✓ This is especially useful for those who have a family history of cancer or other risk factors.

## Why the Onco-D-clare test?

The Onco-D-clare test has shown remarkable reliability of results. It has been clinically validated with an approximate accuracy of 93%, ensuring that its insights are rooted in precision and scientific rigor.

The Onco-D-clare test empowers you with knowledge by offering a nuanced understanding of your cancer risk and the means to chart a proactive course toward a healthier future.

Onco-D-clare plays a crucial role in cancer care approaches and improving patient outcomes.

# Test Details

**Sample type**
Peripheral blood

**Sample size**
5-8ml of peripheral blood

**Cancer type**
All types of cancer except brain and CNS (central nervous system) cancers

**Analysis period**
Approx. 7 days

**Final results**
7-10 days after sample delivering



# Paving the way for personalizing treatment protocols

## Onconomics Plus test

# Onconomics Plus

Onconomics Plus offers a comprehensive solution for selecting personalized treatment plans. This test evaluates the chemosensitivity of both conventional drugs and natural substances, determining the effectiveness of various chemotherapeutic agents. Additionally, it assesses tumor cell sensitivity to natural extracts, identifying which supplements are beneficial. The test also provides insights into the effectiveness of hyperthermia and radiation treatments on cancer, integrating this information with genetic data for a holistic approach to therapy selection.




## How does Onconomics Plus work?

- ✓ Onconomics Plus enables the individualized treatment of patients' cancers using both conventional chemotherapies as well as natural therapies.

Assist decision-making between the doctor and the patient on the best way forward and offer insightful treatment options.

The test equips the team with the knowledge to make informed decisions, maximizing the likelihood of success and minimizing guesswork. It helps determine which supplements or chemotherapy treatments are likely to succeed and which are likely to fail.

# Test Details

**Sample type**
Blood, Tissue for CNS primary tumors

**Sample size**
15-25ml blood, >400mg tissue

**Cancer type**
Applicable for all cancer types

**Analysis period**
Approx. 7 days

**Final results**
7-10 days after sample delivery

- ✓ This test assists physicians in determining the best possible treatment approach for each individual situation.
- ✓ The results categorize the effectiveness of a chemotherapy agent as follows: below 30%, 31-80%, and above 80% effectiveness against cancer.

Onconomics Plus → looks for → Chemosensitivity of anti-cancer drugs and natural substances → Clinicians with a clear analysis of each treatment given

## How does Onconomics Plus help?

- ✓ Onconomics Plus compiles extensive data on the effectiveness of conventional treatments, distinguishing between effective and ineffective options. It also provides insights into natural compounds that can effectively combat cancer.
- ✓ The artful selection of conventional and natural agents, when combined, creates a comprehensive treatment plan addressing the cancer, targeting cancer stem cells, and mitigating the spread of the disease.

## Why choose the Onconomics Plus test?

Through a combination of three assessments, the test evaluates oncogene and the chemosensitivity of anti-cancer drugs and natural substances.




Let us work with your healthcare provider to deliver a range of personalized tests so you can choose the best treatment together.

Telephone
+65 8084 6380

Email
info@rgcc-seasia.com


RGCC's sensitive cell count test identified my patient's malignant breast cancer cells.
- Dr. Tristin Wallace, ND Inspiration Health & Wellness

# Assessing the chemotherapeutic substances' efficacy

## Onconomics test



# Onconomics

Onconomics examines which chemotherapy works best, and which is ineffective for cancer. It offers a detailed, easy-to-use summary of the effectiveness of a given chemotherapy agent. Its goal is to help the clinician select the most potent chemotherapy or combination of chemotherapies for a given situation, knowing that not all tumors behave the same way.




## How does Onconomics works?

- ✓ The Onconomics test employs a dual approach, combining molecular and cellular methods to assess the effectiveness of various cancer therapies.
- ✓ The process involves the isolation of malignant cells through Fluorescence-Activated Cell Sorting (FACS) and negative selection. Then, It is followed by epigenetic analysis and viability assays which determine how well specific treatments can suppress cancer.

- ✓ The isolated cells are then expanded and divided into two groups: one set undergoes viability assays, while the other is subjected to transcriptomic microarrays which assess the genetic and genomic profile.

 Onconomics → looks for → Performance of anticancer drugs and therapies → Clinicians to determine the effective treatment

## How does Onconomics help?

- ✓ Onconomics helps in navigating the cancer treatment with ease and confidence. It's not just about treatment; it's about precision, effectiveness, and tailored care for every individual.
- ✓ The test guides you toward the most effective and personalized treatment options.

## Why the Onconomics test?

Onconomics assesses the genome profile using a dual approach to evaluate specific cancer treatments and drugs.

It offers an in-depth breakdown of the most suitable and successful treatment options for cancer.

It serves as a guide to the treating physician as to the most effective chemotherapy vs a standard protocol which may not work as well. This is particularly important when second/third line treatments are used and found ineffective.

It provides insights to target the cancer when it has mutated beyond current standard protocols; eliminating the need for guesswork

# Test Details

**Sample type**
Blood, Tissue for CNS primary tumors

**Sample size**
15-25ml blood,
> 400mg tissue

**Cancer type**
Applicable for all cancer types

**Analysis period**
Approx. 7 days

**Final results**
7-10 days after sample delivery

# Choose the most effective cancer treatment and therapies with Onconomics

Let us work with your healthcare provider to deliver a range of personalized tests so you can choose the best treatment together.

Telephone
+65 8084 6380

Email
info@rgcc-seasia.com

> I contracted colon cancer in 2018 and had a late stage 3 tumor removed in 2019. I used your protocol of 9 enzymes and just passed 5 years cancer free. My last colonoscopy picked up a polyp, upon examination they found zero cancer cells in the polyp. Thank you very much for what you do you saved my life.
>
> **- T.W**

# Discover effective natural substances to target cancer

## Onconomics Extracts test

# Onconomics Extracts

The Onconomics Extracts test is a unique test that provides precise information on the effectiveness of natural substances in treating cancer. Many patients who have cancer are simultaneously taking supplements. This test can be beneficial for the patient and the treating physician as it indicates the effectiveness of a particular natural substance on the cancer cells. This guide would remove a large amount of guesswork involved as well as the number of tablets that may not work in a particular case.




## How does Onconomics Extracts works?

- ✓ The test pairs your Circulating Tumor Cells (CTCS) with a selection of extracts that may be used to combat cancer.
- ✓ By analyzing how these extracts interact with your specific CTCs, we determine which natural substances are most effective at halting the circulation of these tumor cells. The tested natural substances are divided into Class I

(Cytotoxic agents), Class II (Immunostimulants), and Class III (PK Inhibitors).

✓ The result is a personalized analysis of the natural therapies and supplements that can aid in your battle against cancer.

Onconomics Extracts → analyzes → The performance of natural extracts. → Clinicians to determine the effective natural substances for your treatment

## How does Onconomics Extracts help?

✓ Onconomics Extracts is a step towards selecting suitable natural treatments to complement your cancer care. By gaining a deeper understanding of how these natural substances can work in harmony with your existing treatments, you are better equipped to make informed decisions about your health.

## Why the Onconomics Extracts test?

The Onconomics Extracts test focuses on three key aspects:

The test examines how the extracts can inhibit the signals that drive cancer cells to grow and multiply

It assesses how these extracts can stimulate and boost your immune system.

The test equips patients with information about how natural extracts influence the effectiveness of the ongoing cancer treatments.

# Test Details

**Sample type**
Blood, Tissue for CNS primary tumors

**Sample size**
15-25ml blood, >400mg tissue

**Cancer type**
Applicable for all cancer types

**Analysis period**
Approx. 7 days

**Final results**
7-10 days after sample delivery


Let us work with your healthcare provider to deliver a range of personalized tests so you can choose the best treatment together.

Telephone
+65 8084 6380

Email
info@rgcc-seasia.com

"I must express my gratitude and thankfulness for the incredible brilliance of the RGCC team. For my clients, I see a massive difference as I partner with RGCC assessments and walk them through resolving trauma and unresolved stress patterns. I am forever grateful for Dr. Papasotiriou and the RGCC team!

- Dr. Christine Stueve, D.PSc., PhD, ND, DMBM
Founder NSIPM, Sano Consulting & Wellness Center, Lakeville, USA

# Explore natural treatment options to fight cancer

## Onconomics Extracts+ test

# Onconomics Extracts +

Onconomics Extracts Plus is an advanced panel which offers invaluable insights into identifying optimal natural treatments for cancer. With a focus on over 50 natural extracts and substances, Onconomics Extracts Plus provides detailed information on their efficacy as anticancer agents. By creating individualized profiles based on gene expressions of cancer cells, Onconomics Extracts Plus sheds light on cancer behavior within the body.




## How does Onconomics Extracts+ works?

- ✓ Onconomics Extracts+ test begins with a simple blood sample obtained through liquid biopsy. This sample undergoes analysis to identify CTCs and understand their resistance or sensitivity against cancer cells.
- ✓ It analyzes the gene expression patterns of your cancer cells through a liquid biopsy.

- ✓ The test assesses how specific cancer behaves and evolves within your body. This personalized analysis helps predict how your cancer may respond to various natural treatments.

 Onconomics Extracts+ → looks for → Effective natural extracts → helps clinicians to target cancer cells in natural way

## How does Onconomics Extracts+ help?

- ✓ By assessing the sensitivity to over 50 natural extracts and substances, this test not only evaluates sensitivity to natural extracts but also provides insights into cancer-related gene profiling at the epigenetic level.
- ✓ By analyzing cancer behavior within the body, Onconomics Extracts Plus test offers a deeper understanding of the cancer's genetic behavior within the body and potential of natural remedies in combating cancer.

## Why the Onconomics Extracts+ test?

The test explores a range of natural substances alongside conventional therapies, providing a comprehensive overview of potential treatment options. By analyzing the efficacy of natural substances on cancer, Onconomics Extracts Plus analyzes the genetic behavior of specific cancers and provides an individualized profile

Onconomics Extracts+ empowers clinicians by providing precise information on treatments tailored to individual patients.

It empowers patients by providing comprehensive information on the effectiveness of various natural substances for their cancer.

# Test Details

**Sample type**
Blood, Tissue sample for CNS tumors

**Sample size**
15-25ml of whole peripheral blood

**Cancer type**
All types of cancer

**Analysis time**
7 days in the lab

**Turnaround time**
7-10 days after sample collection


Let us collaborate with your healthcare provider to offer a range of personalized tests, helping you choose the best treatment together.

Telephone
+65 8084 6380

Email
info@rgcc-seasia.com

> Patient D.T. was diagnosed with stage 3a lung cancer in early 2021, I ordered Oncotrace and Onconomics Plus. Her baseline CTC was 4.4 cells/ml. She began a plan of IV therapies and customized supplements based on her Onconomics report. We repeated Oncotrace in Jan 2022, and her CTC count had decreased to 3.9. In August 2022, CTC was 3.5, and then in April 2023, CTC was down to 3.1. The patient is doing well and is so happy to have a quantifiable measure of her post-chemo treatments.
>
> – Dr. Mila McManus, MD
> Founder, The Woodlands Institute for Health & Wellness

# A powerful tool for monitoring treatment progression

## Oncotrace test



# Oncotrace

Oncotrace is an important step in the management and follow-up of a cancer treatment regimen. It gives us information on the current Circulating Tumor Cells (CTCs) count as well as the profile of how aggressive these cells are through the study of the Cancer Stem Cell (CSC) markers. By studying cancer behavior, doctors and patients can monitor the status of tumor markers responsible for migration, proliferation, resistance, and metastasis.




## How does Oncotrace work?

- ✓ A blood sample is taken to examine the presence and immunophenotype of Circulating Tumor Cells.
- ✓ Although the enumeration of CTCs is really important, their immunophenotype analysis provides really useful information as well.

- ✓ This is called immunophenotyping. This analysis unravels vital information on the cancer's nature, probability of metastatic spread, and likelihood of being chemo resistant.




## How does Oncotrace help?

- ✓ Follow-up tool to monitor the cancer disease burden.
- ✓ Assessment of cancer treatment response.
- ✓ Early warning test for relapse and recurrence.
- ✓ The study of Cancer Stem Cell (CSC) markers helps us understand tumor behavior.

## Why choose the Oncotrace test?

It alerts the treating physician of the effectiveness of the current treatment protocol, allowing them to make the necessary adjustments

It identifies the nature and number of CTCs, providing an idea of how advanced the cancer is. It also informs us of the likelihood of metastatic spread. It helps in monitoring and understanding the disease progression, facilitating timely intervention.

With this test, the physician and the patient would have insights on the effectiveness of a particular treatment, allowing them to decide whether any changes need to be made.

# Test Details

**Sample type**
Whole peripheral blood sample

**Sample size**
15-25ml of whole peripheral blood

**Cancer type**
Applicable for all cancer types

**Analysis period**
Approx. 7 days

**Final results**
7-10 days after sample delivery



# A pathway to personalized, effective, and precise cancer care

Let us work with your healthcare provider to deliver a range of personalized tests so you can choose the best treatment together.

**Telephone**
+65 8084 6380

**Email**
info@rgcc-seasia.com

> RGCC cancer testing has totally revolutionized our understanding of a client's particular cancer. With RGCC's advanced testing, we are now able to create personalized cancer treatment protocols for each patient.
>
> – Dr. Clayton Bell, M.D. Integrative & Functional Medicine Physician, Forum Health

# An interim monitoring test to check treatment effectiveness

## Oncocount test



# Oncocount

Oncocount is a useful tool for physicians and patients alike. The test detects the presence of Circulating Tumor Cells (CTCs) and quantifies their concentration in the bloodstream, offering vital information. A higher number of CTCs might be associated with a greater spread of cancer.




## How does Oncocount works?

- ✓ Oncocount detects the presence of CTCs and their concentration in the blood. It is used for diagnostic, monitoring and treatment efficacy purposes.
- ✓ Oncocount provides two crucial pieces of information: the presence of CTCs and their concentration.
- ✓ At RGCC, we employ the cutting-edge fluorescence-activated cell sorting technology to isolate CTCs. This process yields a sample of cells that are 97-99% pure and 99% viable, paving the way for further tests like molecular analysis,

immunophenotyping, gene expression assays, and sensitivity assessments of various treatment agents.

Oncocount → looks for → Circulating Tumor Cells and their concentration → Clinicians monitor cancer progression and relapse

## How does Oncocount help?

- ✓ Follow-up tool to monitor the cancer disease burden.
- ✓ Assessment of cancer treatment response.
- ✓ Early warning test for relapse and recurrence.

## Why the Oncocount test?

Oncocount uses cutting-edge technologies to identify and confirm the presence of CTCs for better assessment of cancer progression and relapse.

The test is used to detect the presence of Circulating Tumor Cells (CTCs) and their concentration in blood.

It monitors patients' status post-treatment while assessing the risk of recurrence.

Doctors turn to this test to gain critical insights into the effectiveness of cancer treatments and the potential for recurrence.

# Test Details

**Sample type**
Whole peripheral blood sample

**Sample size**
10-15ml of whole peripheral blood

**Cancer type**
Applicable for all cancer types

**Analysis period**
Approx. 7 days

**Final results**
7-10 days after sample delivery




Let us work with your healthcare provider to deliver a range of personalized tests so you can choose the best treatment together.

Telephone
+65 8084 6380

Email
info@rgcc-seasia.com

# Assessing treatment efficacy of a patient's specific cancer

## Oncotrail test



# Oncotrail

Oncotrail is an investigation tool that builds on the original Oncotrace. It is designed for specific cancers, i.e. Breast, Colon, GI, Melanoma, Prostate, and Sarcoma. The purpose of the test is to benchmark the aggressiveness of these tumors as well as to track the current management of these cancers. We use this test to monitor these cancers during chemotherapy as well as when a patient is in remission. It checks for Circulating Tumor Cells (CTCs) and provides genetic insights into the nature of the CTCs.




## How does Oncotrail work?

- ✓ A blood sample is analyzed to identify the presence and concentration of CTCs in the blood. This gives us an idea of the trend of cancer.
- ✓ Oncotrail also allows for immunophenotyping of the cancer cells, meaning that we can elucidate the nature of the cancer colls which would give us information on how aggressive each cell is.

- ✓ This test serves as an assessment of the current status of specific types of cancer.

Oncotrail → looks for → Concentration of CTCs and their immunophenotype → Clinicians with a clear analysis of each treatment given

## How does Oncotrail help?

- ✓ Tool to monitor the cancer disease burden.
- ✓ Assessment of cancer treatment response.
- ✓ Early warning test for relapse and recurrence.
- ✓ Cancer Stem Cell (CSC) markers study on specific cancer will help us to monitor the nature of the tumor behavior.

## Why choose the Oncotrail test?

**Oncotrail has undergone rigorous evaluation to ensure high sensitivity, and specificity, making it an invaluable tool for diagnostic purposes.**

Through high-precision techniques, the test is used to monitor the effectiveness of a particular cancer treatment. This objectively provides information on how well the treatment Is going.

This non-invasive tracking of the cancer status notifies the treating physician whether there is a need to adjust the current treatment plan. This helps ensure that the best treatment plan is followed in a timely manner.

# Test Details

**Sample type**
Whole peripheral blood sample

**Sample size**
10-15ml of whole peripheral blood

**Cancer type**
Applicable for all cancer types

**Analysis period**
Approx. 7 days

**Final results**
7-10 days after sample delivery

# Take the first step towards comprehensive cancer management

Let us work with your healthcare provider to deliver a range of personalized tests so you can choose the best treatment together.

Telephone
+65 8084 6380

Email
info@rgcc-seasia.com

# Reserve your 30 minute free consultation and get started with a personalized approach for your cancer

- RGCC accredited expert
- One-One consultation
- Value-packed 30 minutes
- Personalized suggestions

# Understanding a patient's genomes with this precision tool

## aCGH test

# aCGH

Array Comparative Genomic Hybridization (aCGH) test, a microarray-based technique and the most precise tool available today that helps to detect, the unbalanced structural and numerical chromosomal abnormalities that exist in cancer cells. The test is particularly helpful when a patient may be diagnosed with a cancer of unknown origin. In such cases, aCGH helps point the doctor in the right direction by identifying chromosomal abnormalities associated with specific types of cancer.




## How does aCGH work?

- ✓ The aCGH is used to identify chromosomal abnormalities in a patient that could lead to cancer.
- ✓ It analyzes the differences between a patient's DNA and the reference control DNA and provides unique and personalized chromosomal analysis results.

- ✓ The process involves isolating circulating tumor cells (CTCs) from blood, extracting their DNA, and analyzing genetic characteristics through a microarray-based technique.

 aCGH → looks for → Chromosomal aberrations → Clinicians to identify the origin of the primary tumor

## How does aCGH help?

- ✓ The test result provides experts with a clear understanding of the patient's genomes.
- ✓ It helps in the detection of the primary origin of the tumor.
- ✓ It can be a powerful tool in the fight against cancer.

## Why the aCGH test?

aCGH is a specific molecular cytogenetic method for screening the genome and identifying any abnormalities which might be associated with cancer.

With the detection of abnormalities in the chromosomes, aCGH enables us to identify the primary origin of the tumor.

It enables precise and fast detection of abnormalities in the entire genome sequence with very high resolution.

It provides clinicians with personalized chromosomal analysis for their patients' unique cancer journey.

## Test Details

**Sample type**
Whole peripheral blood sample

**Sample size**
10-15ml of whole peripheral blood

**Analysis time**
Approx. 2-3 weeks

**Final results**
3-4 weeks after sample delivery


The key to effectively treating cancer lies in personalized medicine using the information in a patient's genes.
- Dr Ioannis Papasotiriou
Director of RGCC, International GmbH

> Part of my challenge has been to seek state of the art diagnostic tools that can help my patient heal faster. It is without any obstacle or any limitation that this constant pursuit of scientific advancement led me to RGCC, and I am profoundly grateful to the team, scientific board and the founder for developing something so unique and so precise that allows me to truly help my patients thrive."
>
> - Dr. Ana Paz
> White Clinic, Lisbon, Portugal

# Know how a body responds to anti-cancer drugs

## ChemoSNiP test



# ChemoSNiP

When a drug is administered to the body, the body responds to the drug itself. Not every patient responds to chemotherapy identically. ChemoSNIP looks at how our body responds to a chemotherapy agent. This tells us whether our body removes the agent rapidly, reducing its effectiveness or detoxing poorly, resulting in higher chances of toxicity. ChemoSNIP allows al clinician to analyze how a patient's body reacts to the specific drug.




## How does ChemoSNiP works?

- ✓ The human body commonly has variants that make us different from one another. These variants are called SNPs or single nucleotide polymorphisms. SNPs can make us respond differently to chemicals (drugs) when administered to the body.
- ✓ These are also responsible for the metabolism / detoxification of cytostatic or targeted drugs used in cancer therapy.

- ChemoSNiP examines these potential SNPs which affect how our body manages a drug, providing an exclusion criterion for chemotherapy that either may not work well or end up being excessively toxic to the body. It thus helps clinicians make superior personalized decisions on medication would work best and even modify dosages to prevent excessive toxicity.


## How does ChemoSNiP help?

- The test result provides doctors with valuable insight into identifying the drug that can be activated and then metabolized by patient's body.
- ChemoSNiP provides information to the treating oncologist indicating whether a particular chemotherapy would be highly toxic (the patient is unable to detox and clear the chemotheraphy) or ineffective (as the patient would clear off the chemotheraphy rapidly compared to the normal population) to a particular patient.
- Through personalized analysis, the test enables us to determine the treatment that is most suitable for a patient.

## Why the ChemoSNiP test?

With molecular biology-based assays, ChemoSNiP has the effectiveness to locate and analyze the SNPs.

The study of SNPs helps indicate which chemotherapeutic treatments would benefit the patient with the least risk of adverse side effects.

Provides insights and personalized analysis of drugs and treatments for each patient.

# Test Details

**Sample type**
Whole peripheral blood sample or swab sample

**Sample size**
10-15ml of whole peripheral blood or 2 swabs

**Cancer type**
Applicable for all cancer types

**Analysis period**
Approx. 6-8 working days

**Final results**
10-12 days after sample delivery

# Get a step closer to beating cancer with ChemoSNiP

Let us work with your healthcare provider to deliver a range of personalized tests so you can choose the best treatment together.

**Telephone**
+65 8084 6380

**Email**
info@rgcc-seasia.com


"For us, our interest is what we could do better than the protocols available in the clinical practice, so we can create better treatments, no matter whether we use current drugs or develop new treatments."
– Dr Ioannis Papasotiriou
Director of RGCC,International GmbH

# Assessing the status of the immune system

## Immune-Frame test



# Immune-Frame

The human immune system is the 'police' that fights cancer as well as pathogens from the human body. Individuals who have cancer have a suppressed immune system especially when they undergo chemotherapy. Immune-Frame provides insights into the current state of a person's immune system. These precise insights of the immune status guide the selection or exclusion of therapies, that would better suit a given situation in relation to the ability of the human body to clear out the tumor cells.




## How does Immune-Frame work?

- ✓ The Immune-Frame is designed to assess the suitability of a patient for immunotherapy or cellular therapies. It provides information about the status of the immune system of the patient.
- ✓ This evaluation employs ELISA assay and flow cytometry methods to gauge the status of the Immune system.

- ✓ This test accurately identifies the cell types that are currently in play in the regulation of the immune system. This allows the physician to adjust current treatments and recommend modifications that customize the immunity to better serve the patient.

Immune-Frame → looks for → Specific Immunity Markers → Clinician with the suitability of a particular immune or cellular therapy

## How does Immune-Frame help?

- ✓ Immune-Frame evaluates the strengths and weaknesses of the immune system in its entirety. This is vital to cancer survival and the selection of precise various immunotherapeutic options. The proper functioning of the immune system is vital to the elimination of current and future cancer cells.

- ✓ With the test results, doctors can optimize their patient treatments.

## Why choose the Immune-Frame test?

Immune frame delivers an in-depth assessment of a patient's immune system's condition and status.

The test analyzes blood samples to detect cytokines produced by specific cells.

With the identification of blood-borne markers, it helps determine the eligibility of cancer patients for immunotherapies.

It allows clinicians to evaluate the immune system and optimize treatments for cancer patients.

# Test Details

**Sample type**
Whole peripheral blood sample

**Sample size**
15-25ml of whole peripheral blood

**Cancer type**
Applicable for all cancer types

**Analysis period**
Approx. 7 days

**Final results**
7-10 days after sample delivery




Let us work with your healthcare provider to deliver a range of personalized tests so you can choose the best treatment together.

Telephone
+65 8084 6380

Email
info@rgcc-seasia.com

# 7 steps
## to get personalized cancer testing

**01** Arrange an appointment with your doctor or contact one from RGCC SEA network.

**02** You visit your doctor for a blood test.

**03** The blood sample is sent to our state-of-the art laboratory in Europe.

**04** Our scientists carry out a range of personalised tests on your sample to detect any potential early signs of cancer, or monitor any existing cancer.

**05** We produce a profile of treatments that could benefit you.

**06** We share your test results and profile with your doctor and you.

**07** You and your doctor develop a personalised approach to your cancer diagnosis together.

# Predicting secondary tumor growth and its potential location

## Metastat test



# Metastat

Metastatic spread has a very poor prognosis and it would be pertinent to know if this is of high or low probability. Metastat investigates the proteins that are related to the distant spread of cancer. This is an advanced investigation to clarify the nature of a certain cancer. Being equipped with this knowledge, the treating physician takes into consideration the potential metastatic properties of cancer cells.




## How does Metastat works?

- ✓ Metastasis is a stage where tumors begin to Infiltrate other organs. This Metastat test is designed to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumor is likely to develop and its potential location.
- ✓ By analyzing a blood sample, we meticulously examine and identify Circulating Tumor Cells (CTCs).

- ✓ The test employs a dual approach to scrutinize your blood sample. Using Polymerase Chain Reaction (PCR) to gauge specific marker levels and flow cytometry to identify the protein levels of specific genes, this comprehensive analysis ensures precision in evaluating the cancer's progression.

 Metastat → looks for → CTCs with metastatic potential → Clinicians with detailed insights into treatment approach intensity

## How does Metastat help?

- ✓ The Metastat test quantifies the ability of the cancer to spread throughout the body. It is vital in the survival of the patient to be able to understand this component, as metastasis considerably lowers life expectancy. Hence, understanding the probability of metastasis would help determine how aggressive a treatment needs to be.

- ✓ It arms both doctors and cancer patients with the Information needed to take proactive measures and make informed decisions.

## Why the Metastat test?

Metastat is a valuable tool suitable for all patients who have received a confirmed cancer diagnosis.

It provides comprehensive information on tumor cells using blood-borne markers.

It provides a timely assessment of secondary cancer or tumor development.

It paves the way for more tailored and effective cancer treatments for each patient.

# Test Details

**Sample type**
Whole peripheral blood sample

**Sample size**
10-15ml of whole peripheral blood

**Cancer type**
Applicable for all cancer types

**Analysis period**
Approx. 7 days

**Final results**
7-10 days after sample delivery

## Get the insights you need for the fight against cancer,

Let us work with your healthcare provider to deliver a range of personalized tests so you can choose the best treatment together.

Telephone
+65 8084 6380

Email
info@rgcc-seasia.com

> From the moment I stepped into the Clinic, I knew I was in good hands, as they work closely with RGCC Laboratory. Their dedication to precision and personalized care is unmatched. Thanks to their tests, my treatment plan was tailored specifically to my needs, giving me the best possible chance at beating cancer. I'm forever grateful for their expertise and support during this challenging time.
>
> **- S.L**

# Determining a patient's sensitivity to cancer therapies

## CAMBISeq test



# CAMBISeq

CAMBISeq utilizes an advanced technique called Next-Generation Sequencing (NGS) to uncover the genetic mutations of a tumor by analysis of DNA and RNA to provide clinicians with important insights. It uses a patient's genetic information to predict their response to targeted therapy and immunotherapy. This test identifies variations in genes that our scientists use as biomarkers to assess sensitivity to different types of conventional therapies.




## How does CAMBISeq work?

- ✓ CAMBISeq uses next-generation sequencing technology in circulating tumor cells and analyses more than 500 genes at DNA and RNA level, providing useful information for sensitivity in Immunotherapy and targeted therapies.
- ✓ It digs deep into a patient's genetic makeup, covering over 500 genes and thousands of variants that can significantly impact the success of cancer treatments.

- ✓ It assesses multivariant types in a single assay and detects variants at low variant allele frequency. These specific biomarkers guide clinicians toward treatments with the highest potential to combat the patient's unique cancer.
- ✓ It covers different types of cancer (lung, breast, colon, myeloid, sarcoma etc.) in one test.

CAMBISeq → looks for → Variants and fusions → Clinicians with the selection of appropriate targeted therapy or immunotherapy

## How does CAMBISeq help?

- ✓ CAMBISeq identifies variants in over 500 genes, detects fusions, and calculates the Tumor Mutational Burden (TMB) and Microsatellite Instability Status (MSI).
- ✓ Identification of specific mutations that help in designing personalized targeted therapies that have the highest chances of treatment.
- ✓ Provides a Tumour Mutational Burden score, an emerging quantitative genomic information used to predict sensitivity to checkpoint inhibitors (immunotherapies).

## Why the CAMBISeq test?

CAMBISeq empowers scientists and clinicians to decode genetic information by providing the Tumor Mutational Burden score and Microsatellite Instability Status.

With this critical data, clinicians can tailor therapies to provide the most effective and personalized care.

The test ultimately enhances the patient's chances of a successful battle against cancer.

# Test Details

**Sample type**
Blood, Tissue,
FFPE tissue

**Sample size**
10-15ml blood,
> 400mg tissue
100mg FFPE tissue

**Cancer type**
Applicable for
all cancer types

**Analysis period**
Approx. 2-3 weeks

**Final results**
2-4 weeks




Let us work with your healthcare provider to deliver a range of personalized tests so you can choose the best treatment together.

Telephone
+65 8084 6380

Email
info@rgcc-seasia.com

# Shaping the cancer care paradigm

At RGCC, we strongly believe that personalized medicine is the future of cancer treatment. To improve the chances of successful treatment and survival, RGCC services specializes in designing personalized cellular therapies based on RNA interference.

Our team of scientists and medical experts conducts precise and reliable genetic tests to study cancer cells at all levels, including variants (DNA) and gene expression (mRNA).

We're dedicated to developing accurate tests that can help detect cancer in its early stages and save lives.


## HEADQUARTERS

**RGCC International GmbH**
Baarerstrasse 95,
6300 Zug, Switzerland
office@rgcc-international.com
+41 (0) 41 725 0560

## LABORATORY FACILITIES

**Florina, Greece**
**Halle, Germany**
**Hyderabad, India**
**Baar, Switzerland**

## RGCC REGIONAL OFFICE

**RGCC Southeast Asia**
2 Venture Drive #09-27 Vision Exchange
Singapore 608526
info@rgcc-seasia.com
+65 8084 6380


Member of RGCC GROUP

rgccsea.com